The latest price target for Corcept Therapeutics (NASDAQ:CORT) was reported by UBS on December 16, 2025. The analyst firm set a price target for $95.00 expecting CORT to rise to within 12 months (a possible 15.85% upside). 19 analyst firms have reported ratings in the last year.

The latest analyst rating for Corcept Therapeutics (NASDAQ:CORT) was provided by UBS, and Corcept Therapeutics initiated their neutral rating.

The last upgrade for Corcept Therapeutics Inc happened on November 6, 2023 when Truist Securities raised their price target to $38. Truist Securities previously had a hold for Corcept Therapeutics Inc.

The last downgrade for Corcept Therapeutics Inc happened on February 15, 2023 when Jefferies changed their price target from $35 to $22 for Corcept Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corcept Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corcept Therapeutics was filed on December 16, 2025 so you should expect the next rating to be made available sometime around December 16, 2026.

While ratings are subjective and will change, the latest Corcept Therapeutics (CORT) rating was a initiated with a price target of $0.00 to $95.00. The current price Corcept Therapeutics (CORT) is trading at is $82.00, which is within the analyst’s predicted range.